Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.

Cancer medicine - 1 Dec 2021

Grote Isabel, Bartels Stephan, Kandt Leonie, Bollmann Laura, Christgen Henriette, Gronewold Malte, Raap Mieke, Lehmann Ulrich, Gluz Oleg, Nitz Ulrike, Kuemmel Sherko, Zu Eulenburg Christine, Braun Michael, Aktas Bahriye, Grischke Eva-Maria, Schumacher Claudia, Luedtke-Heckenkamp Kerstin, Kates Ronald, Wuerstlein Rachel, Graeser Monika, Harbeck Nadia, Christgen Matthias, Kreipe Hans

Abstract excerpt

BACKGROUND: Whereas the genomic landscape of endocrine-resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non-responsiveness to endocrine treatment in luminal early breast cancer. METHODS: In this study, 622 estrogen receptor-expressing breast cancer cases treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Breast Neoplasms

Share to Drug Resistance, Neoplasm

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Neoplasm Staging

Share to Tamoxifen

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 34779146
DOI: 10.1002/cam4.4376
PMCID: PMC8633262

Genes

TP53
ERBB2
ARID1A
BRAF
CCND1
ESR1
FGFR1
GATA3
HRAS
KRAS
NRAS
PAK1
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.PMID 34779146Read ↗

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.Semantic proximity Read ↗

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity Read ↗

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.Semantic proximity Read ↗

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.Semantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.Semantic proximity Read ↗

Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.Semantic proximity Read ↗

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.